Anthem Biosciences IPO sets price band at ₹540-₹570 per share; check lot size, key dates and more

Anthem Biosciences IPO: The initial public offering of Anthem Biosciences will open for public subscription on Monday, July 14. The issue will conclude on Wednesday, July 16. It has announced a price band of ₹540-₹570 per share.

According to the red herring prospectus (RHP), the bidding for anchor investors would take place on July 11.

The ₹3,395 crore initial share sale is entirely an offer for sale (OFS) of 59,561,404 shares by promoters, investors and other selling shareholders.

Since there is no fresh issue component, the company will not get any funds from the public offer, and the proceeds will go to the selling shareholders.

Anthem Biosciences IPO: Lot size

A lot consists of 26 equity shares.

The company has reserved 50% of the offer for qualified institutional buyers (QIBs), 35% for retail individual investors (RIIs) and 15% for non-institutional investors.

Anthem Biosciences IPO key dates: Allotment and listing date

The basis of allotment is likely to be finalised on July 17, while the listing on the BSE and the NSE would take place on July 21.

The issue's book-running lead managers are JM Financial Ltd, JP Morgan India, Nomura Financial Advisory and Securities (India) Pvt Ltd and Citigroup Global Markets India. KFin Technologies is the registrar.

About the company

Anthem Biosciences is a Contract Research, Development, and Manufacturing Organisation (CRDMO) with operations spanning drug discovery, development, and manufacturing. The company is into the manufacturing and selling of complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs) such as enzymes, peptides, probiotics, nutritional actives, biosimilars and vitamin analogues.

Divi's Laboratories, Sai Life Sciences Ltd, Suven Life Sciences and Syngene International are the listed peers of Anthem Biosciences.

Incorporated in 2006, the firm has two operational manufacturing plants located in Karnataka.

The drugmaker's revenue from operations climbed by 30% to ₹1,844 crore in the financial year 2024-25 from ₹1,419 crore in the previous fiscal. The profit after tax rose 23% year-on-year (YoY) to ₹451 crore in FY25.